Skip to content

Advertisement

Featured article: Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin

Bullous hemorrhagic dermatosis (BHD) is a systemic side-effect of low molecular weight heparin, characterized by multiple intra-epidermal hemorrhages distant from the site of injection. There have been several small case series and literature reviews on BHD, but none have captured a complete set of reported patients. Here, Dr. Russo et al. sought to describe a case of BHD with late diagnosis and completely summarize the existing English and Spanish literature with searches of Pubmed, Scopus, Ovid Embase and Ovid Medline.

Articles

  1. Content type: Case report

      |  

    Authors: Kamal Chamoun, Sanam Loghavi, Naveen Pemmaraju, Marina Konopleva, Michael Kroll, Madeleine Nguyen-Cao, Marisa Hornbaker, Courtney D. DiNardo, Tapan Kadia, Jeffrey Jorgensen, Michael Andreeff, Shimin Hu and Christopher B. Benton

Most accessed articles RSS

View all articles

Editors-in-Chief

Zihai Li, Medical University of South Carolina
Delong Liu, New York Medical College
Kongming Wu, Tongji Medical College

Aims & scope

Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.

Experimental Hematology & Oncology is the companion journal of Journal of Hematology & Oncology.

Editor's quote

"Like our companion journal, Journal of Hematology & Oncology, Experimental Hematology & Oncology publishes on all aspects of hematology and oncology, which are closely intertwined and rapidly evolving fields. Experimental Hematology & Oncology also emphasizes basic and translational research, as well as patient-oriented research and clinical trials with ‘negative’ or preliminary results. The journal is an international platform for sharing findings in these areas and adheres to fast turnaround times."

Delong Liu

Advertisement

2017 Journal Metrics

Advertisement